X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Torrent Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs TORRENT PHARMA - Comparison Results

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA TORRENT PHARMA AJANTA PHARMA/
TORRENT PHARMA
 
P/E (TTM) x 24.0 27.6 86.8% View Chart
P/BV x 9.9 5.2 188.3% View Chart
Dividend Yield % 0.6 1.0 58.5%  

Financials

 AJANTA PHARMA   TORRENT PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
TORRENT PHARMA
Mar-17
AJANTA PHARMA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1,7201,768 97.3%   
Low Rs1,1031,186 93.0%   
Sales per share (Unadj.) Rs194.6346.1 56.2%  
Earnings per share (Unadj.) Rs45.255.2 82.0%  
Cash flow per share (Unadj.) Rs50.373.3 68.6%  
Dividends per share (Unadj.) Rs8.0014.00 57.1%  
Dividend yield (eoy) %0.60.9 59.8%  
Book value per share (Unadj.) Rs132.0257.1 51.4%  
Shares outstanding (eoy) m88.77169.22 52.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.34.3 170.0%   
Avg P/E ratio x31.226.8 116.6%  
P/CF ratio (eoy) x28.120.1 139.3%  
Price / Book Value ratio x10.75.7 186.1%  
Dividend payout %17.725.4 69.7%   
Avg Mkt Cap Rs m125,299249,887 50.1%   
No. of employees `000NA11.8 0.0%   
Total wages/salary Rs m2,5709,934 25.9%   
Avg. sales/employee Rs ThNM4,971.5-  
Avg. wages/employee Rs ThNM843.2-  
Avg. net profit/employee Rs ThNM792.4-  
INCOME DATA
Net Sales Rs m17,27558,569 29.5%  
Other income Rs m1662,233 7.4%   
Total revenues Rs m17,44260,802 28.7%   
Gross profit Rs m5,80713,773 42.2%  
Depreciation Rs m4513,069 14.7%   
Interest Rs m492,056 2.4%   
Profit before tax Rs m5,47410,881 50.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,4601,545 94.5%   
Profit after tax Rs m4,0149,336 43.0%  
Gross profit margin %33.623.5 143.0%  
Effective tax rate %26.714.2 187.8%   
Net profit margin %23.215.9 145.8%  
BALANCE SHEET DATA
Current assets Rs m7,63953,841 14.2%   
Current liabilities Rs m2,71531,612 8.6%   
Net working cap to sales %28.538.0 75.1%  
Current ratio x2.81.7 165.2%  
Inventory Days Days4397 44.5%  
Debtors Days Days7984 93.9%  
Net fixed assets Rs m6,91442,079 16.4%   
Share capital Rs m177846 20.9%   
"Free" reserves Rs m11,44242,655 26.8%   
Net worth Rs m11,72143,501 26.9%   
Long term debt Rs m14922,408 0.7%   
Total assets Rs m14,814101,250 14.6%  
Interest coverage x112.96.3 1,794.7%   
Debt to equity ratio x00.5 2.5%  
Sales to assets ratio x1.20.6 201.6%   
Return on assets %27.411.3 243.8%  
Return on equity %34.221.5 159.6%  
Return on capital %46.519.6 237.1%  
Exports to sales %55.10-   
Imports to sales %6.00-   
Exports (fob) Rs m9,527NA-   
Imports (cif) Rs m1,038NA-   
Fx inflow Rs m10,42220,066 51.9%   
Fx outflow Rs m1,6785,304 31.6%   
Net fx Rs m8,74414,762 59.2%   
CASH FLOW
From Operations Rs m3,26410,127 32.2%  
From Investments Rs m-2,093-7,869 26.6%  
From Financial Activity Rs m-1,186-1,918 61.8%  
Net Cashflow Rs m-15212 -7.0%  

Share Holding

Indian Promoters % 73.8 71.5 103.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 7.0 22.1%  
FIIs % 7.6 12.6 60.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 8.8 193.2%  
Shareholders   20,968 26,511 79.1%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   NOVARTIS  ASTRAZENECA PHARMA  STRIDES SHASUN LTD  STERLING BIOTECH  JUBILANT LIFE SCIENCES  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Firm; IT Stocks Gain(09:30 am)

Asian stocks were relatively subdued in the early trade today, with most regional indices hovering around the flat line following the softer lead stateside.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Feb 21, 2018 11:37 AM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS